Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults

@article{Dorosch2019EfficacyOA,
  title={Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults},
  author={Tetiana Dorosch and Christine Anne Ganzer and Mei-Hua Lin and Alon Seifan},
  journal={Current Pain and Headache Reports},
  year={2019},
  volume={23}
}
Systematic review of angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARB) in the prophylactic treatment of adults with migraine. To identify gaps in research and provide guidance for future clinical trials. A search was completed using PubMed, MEDLINE, Embase, and the Cochrane Library January 1, 1990 through December 31, 2017. The following are keywords used in the search: migraine, migraine prophylaxis/prevention, renin-angiotensin-aldosterone… 

Preventive Migraine Treatment

  • R. Burch
  • Medicine, Psychology
    Continuum
  • 2021
Many pharmacologic and nonpharmacologic treatment options are available for the prevention of migraine, including newer therapies aimed at the CGRP pathway as well as older treatments with good evidence for efficacy.

Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study

C candesartan showed beneficial effects in the preventive treatment of migraine in clinical practice, including patients with chronic migraine, medication-overuse headache and resistance to prior prophylactics.

Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center

The mild effect of preventive drugs on migraine features and even the number of patients who were lost to follow-up or dropped out because of adverse events confirm that in severe and chronic patients, the first line of prevention can only delay a more focused therapeutic approach.

Migraine review for general practice

Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?

This paper focuses on the co‐existence of comorbidities of COVID‐19, in comparison with migraine, based on a wide clinical dataset and available reports, and discusses mechanisms including potential strategic roles of angiotensin‐converting enzyme 2, angiotENSin‐II, and nucleotide oligomerization domain‐like receptor family, pyrin domain containing 3 inflammasome, playing remarkable parts in the pathogenesis of CO VID‐19 and migraine.

Managing Migraine in the Times of COVID-19 Pandemic

Physicians should be made aware of the new rules of the game in treating migraines during this time of the pandemic so that these patients get optimum treatment and care and don't feel left out.

Evidência dos Modificadores do Sistema Renina-Angiotensina na Prevenção da Enxaqueca Episódica

Introdução: A enxaqueca é uma doença frequente e incapacitante. Modelos experimentais sugerem uma relação entre o sistema renina-angiotensina e o desenvolvimento de enxaqueca. Este artigo tem como

COVID‐19 is a Real Headache!

It is concluded that as a common non‐respiratory symptom of COVID‐19, headache should not be overlooked, and its characteristics should be recorded with scrutiny.

Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19

Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers

To outline strategies for the treatment of migraine which do not require in‐person visits to clinic or the emergency department, and to describe ways that health insurance companies can remove

References

SHOWING 1-10 OF 22 REFERENCES

ACE and ARB Agents in the Prophylactic Therapy of Migraine—How Effective Are They?

Based upon biologic plausibility, the quality of evidence for efficacy from clinical trials, and recommendations in published guidelines, ACE inhibitors and ARBs are considered as second- or third-line options for migraine prophylaxis.

Treatment with telmisartan, a long-acting angiotensin II receptor blocker, prevents migraine attacks in Japanese non-responders to lomerizine

The present study supported that telmisartan treatment had preventive effects in 90% of lomerizine non-responders, and significantly decreased frequency of headache days and headache severity.

Renin angiotensin system: A novel target for migraine prophylaxis

A new class of drugs like angiotensin-converting enzyme inhibitors (ACE inhibitors) and ang Elliotensin II receptor antagonists have recently been studied for their off label use in prophylaxis of migraine and a direction to use these drugs for chronic migraineurs is given.

Inhibitory control of angiotensin-converting enzyme by ramipril in migraine

Ramipril prevented migraine attacks independently from blood pressure, and this result supports a link between renin-angiotensin system and migraine pathophysiology.

Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.

In this study, the angiotensin II receptor blocker candesartan provided effective migraine prophylaxis, with a tolerability profile comparable with that of placebo, with no significant differences in health-related quality of life.

Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial

The results support the previous suggestions on usage of ACE inhibitors in migraine prophylaxis and Enalapril according to its effect in decreasing the frequency, severity, and duration of headaches.

Preventive Pharmacologic Treatments for Episodic Migraine in Adults

Off-label angiotensin-inhibiting drugs and beta-blockers were most effective and tolerable for episodic migraine prevention and limited direct evidence as well as frequentist and exploratory network Bayesian meta-analysis showed no statistically significant differences between approved drugs.

Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?

  • M. Burnier
  • Medicine
    The Journal of international medical research
  • 2009
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET™) showed that the angiotensin II receptor blocker (ARB) telmisartan was as protective as the

Migraine prophylaxis: what is new and what we need?

Tonabersat is likely to be a step forward for the treatment of migraine with aura, however, much work is needed to identify predictive clinical features of successful responsiveness and to better define the duration of prophylaxis.